XTANT MEDICAL HOLDINGS INC (XTNT) Fundamental Analysis & Valuation

NYSEARCA:XTNT • US98420P3082

0.6338 USD
+0.01 (+2.23%)
Last: Mar 9, 2026, 11:53 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This XTNT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Taking everything into account, XTNT scores 3 out of 10 in our fundamental rating. XTNT was compared to 184 industry peers in the Health Care Equipment & Supplies industry. XTNT may be in some trouble as it scores bad on both profitability and health. XTNT has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

3

1. XTNT Profitability Analysis

1.1 Basic Checks

  • In the past year XTNT was profitable.
  • In the past year XTNT had a positive cash flow from operations.
  • In the past 5 years XTNT reported 4 times negative net income.
  • XTNT had negative operating cash flow in 4 of the past 5 years.
XTNT Yearly Net Income VS EBIT VS OCF VS FCFXTNT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

  • XTNT has a better Return On Assets (-4.43%) than 68.48% of its industry peers.
  • XTNT's Return On Equity of -9.44% is fine compared to the rest of the industry. XTNT outperforms 67.93% of its industry peers.
  • XTNT has a better Return On Invested Capital (0.03%) than 64.67% of its industry peers.
Industry RankSector Rank
ROA -4.43%
ROE -9.44%
ROIC 0.03%
ROA(3y)-10.3%
ROA(5y)-11.34%
ROE(3y)-20.61%
ROE(5y)-25.18%
ROIC(3y)N/A
ROIC(5y)N/A
XTNT Yearly ROA, ROE, ROICXTNT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200

1.3 Margins

  • With a decent Operating Margin value of 0.02%, XTNT is doing good in the industry, outperforming 64.67% of the companies in the same industry.
  • XTNT's Gross Margin of 60.16% is fine compared to the rest of the industry. XTNT outperforms 61.96% of its industry peers.
  • XTNT's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 0.02%
PM (TTM) N/A
GM 60.16%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.35%
GM growth 5Y-2.41%
XTNT Yearly Profit, Operating, Gross MarginsXTNT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. XTNT Health Analysis

2.1 Basic Checks

  • XTNT has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • XTNT has more shares outstanding than it did 1 year ago.
  • XTNT has more shares outstanding than it did 5 years ago.
  • XTNT has a worse debt/assets ratio than last year.
XTNT Yearly Shares OutstandingXTNT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
XTNT Yearly Total Debt VS Total AssetsXTNT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

  • Based on the Altman-Z score of -0.76, we must say that XTNT is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of XTNT (-0.76) is comparable to the rest of the industry.
  • XTNT has a Debt/Equity ratio of 0.46. This is a healthy value indicating a solid balance between debt and equity.
  • XTNT's Debt to Equity ratio of 0.46 is in line compared to the rest of the industry. XTNT outperforms 45.11% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF N/A
Altman-Z -0.76
ROIC/WACC0
WACC11.07%
XTNT Yearly LT Debt VS Equity VS FCFXTNT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 2.47 indicates that XTNT has no problem at all paying its short term obligations.
  • The Current ratio of XTNT (2.47) is comparable to the rest of the industry.
  • A Quick Ratio of 1.16 indicates that XTNT should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.16, XTNT is doing worse than 70.65% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.47
Quick Ratio 1.16
XTNT Yearly Current Assets VS Current LiabilitesXTNT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. XTNT Growth Analysis

3.1 Past

  • XTNT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 107.69%, which is quite impressive.
  • XTNT shows a strong growth in Revenue. In the last year, the Revenue has grown by 28.44%.
  • The Revenue has been growing by 12.64% on average over the past years. This is quite good.
EPS 1Y (TTM)107.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%125%
Revenue 1Y (TTM)28.44%
Revenue growth 3Y28.5%
Revenue growth 5Y12.64%
Sales Q2Q%19.04%

3.2 Future

  • Based on estimates for the next years, XTNT will show a very strong growth in Earnings Per Share. The EPS will grow by 30.30% on average per year.
  • Based on estimates for the next years, XTNT will show a small growth in Revenue. The Revenue will grow by 1.69% on average per year.
EPS Next Y121.25%
EPS Next 2Y42.92%
EPS Next 3Y30.31%
EPS Next 5YN/A
Revenue Next Year12.6%
Revenue Next 2Y-1.85%
Revenue Next 3Y1.69%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
XTNT Yearly Revenue VS EstimatesXTNT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
XTNT Yearly EPS VS EstimatesXTNT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2019 2020 2023 2024 2025 2026 2027 0 -5 -10 -15 -20

More info and screens

Find the best growth stocksShow best growing peers

4

4. XTNT Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 63.38 indicates a quite expensive valuation of XTNT.
  • Based on the Price/Earnings ratio, XTNT is valued a bit cheaper than 65.76% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of XTNT to the average of the S&P500 Index (26.29), we can say XTNT is valued expensively.
  • A Price/Forward Earnings ratio of 124.27 indicates a quite expensive valuation of XTNT.
  • 65.22% of the companies in the same industry are more expensive than XTNT, based on the Price/Forward Earnings ratio.
  • XTNT is valuated expensively when we compare the Price/Forward Earnings ratio to 24.60, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 63.38
Fwd PE 124.27
XTNT Price Earnings VS Forward Price EarningsXTNT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

  • XTNT's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. XTNT is cheaper than 71.20% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 25.43
XTNT Per share dataXTNT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8

4.3 Compensation for Growth

  • XTNT's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as XTNT's earnings are expected to grow with 30.30% in the coming years.
PEG (NY)0.52
PEG (5Y)N/A
EPS Next 2Y42.92%
EPS Next 3Y30.31%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. XTNT Dividend Analysis

5.1 Amount

  • XTNT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

XTNT Fundamentals: All Metrics, Ratios and Statistics

XTANT MEDICAL HOLDINGS INC

NYSEARCA:XTNT (3/9/2026, 11:53:29 AM)

0.6338

+0.01 (+2.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-10
Earnings (Next)03-20
Inst Owners57.97%
Inst Owner Change1.68%
Ins Owners15.18%
Ins Owner Change12.38%
Market Cap88.73M
Revenue(TTM)117.27M
Net Income(TTM)-4.58M
Analysts85
Price Target1.53 (141.4%)
Short Float %0.02%
Short Ratio0.15
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)198.04%
Min EPS beat(2)100%
Max EPS beat(2)296.08%
EPS beat(4)2
Avg EPS beat(4)77.12%
Min EPS beat(4)-56.86%
Max EPS beat(4)296.08%
EPS beat(8)3
Avg EPS beat(8)73.86%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)7.07%
Min Revenue beat(2)3.39%
Max Revenue beat(2)10.74%
Revenue beat(4)2
Avg Revenue beat(4)1.19%
Min Revenue beat(4)-6.52%
Max Revenue beat(4)10.74%
Revenue beat(8)6
Avg Revenue beat(8)5.84%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.75%
Valuation
Industry RankSector Rank
PE 63.38
Fwd PE 124.27
P/S 0.69
P/FCF N/A
P/OCF 59.12
P/B 1.83
P/tB 2.63
EV/EBITDA 25.43
EPS(TTM)0.01
EY1.58%
EPS(NY)0.01
Fwd EY0.8%
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)0.01
OCFY1.69%
SpS0.91
BVpS0.35
TBVpS0.24
PEG (NY)0.52
PEG (5Y)N/A
Graham Number0.28
Profitability
Industry RankSector Rank
ROA -4.43%
ROE -9.44%
ROCE 0.04%
ROIC 0.03%
ROICexc 0.03%
ROICexgc 0.04%
OM 0.02%
PM (TTM) N/A
GM 60.16%
FCFM N/A
ROA(3y)-10.3%
ROA(5y)-11.34%
ROE(3y)-20.61%
ROE(5y)-25.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.35%
GM growth 5Y-2.41%
F-Score5
Asset Turnover1.23
Health
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF N/A
Debt/EBITDA 4.97
Cap/Depr 97.07%
Cap/Sales 3.39%
Interest Coverage 0.01
Cash Conversion 33.42%
Profit Quality N/A
Current Ratio 2.47
Quick Ratio 1.16
Altman-Z -0.76
F-Score5
WACC11.07%
ROIC/WACC0
Cap/Depr(3y)93.26%
Cap/Depr(5y)102.58%
Cap/Sales(3y)2.72%
Cap/Sales(5y)2.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)107.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%125%
EPS Next Y121.25%
EPS Next 2Y42.92%
EPS Next 3Y30.31%
EPS Next 5YN/A
Revenue 1Y (TTM)28.44%
Revenue growth 3Y28.5%
Revenue growth 5Y12.64%
Sales Q2Q%19.04%
Revenue Next Year12.6%
Revenue Next 2Y-1.85%
Revenue Next 3Y1.69%
Revenue Next 5YN/A
EBIT growth 1Y100.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year220.68%
EBIT Next 3Y42.24%
EBIT Next 5YN/A
FCF growth 1Y74.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y116.46%
OCF growth 3YN/A
OCF growth 5YN/A

XTANT MEDICAL HOLDINGS INC / XTNT FAQ

Can you provide the ChartMill fundamental rating for XTANT MEDICAL HOLDINGS INC?

ChartMill assigns a fundamental rating of 3 / 10 to XTNT.


What is the valuation status for XTNT stock?

ChartMill assigns a valuation rating of 4 / 10 to XTANT MEDICAL HOLDINGS INC (XTNT). This can be considered as Fairly Valued.


How profitable is XTANT MEDICAL HOLDINGS INC (XTNT) stock?

XTANT MEDICAL HOLDINGS INC (XTNT) has a profitability rating of 3 / 10.


What is the financial health of XTANT MEDICAL HOLDINGS INC (XTNT) stock?

The financial health rating of XTANT MEDICAL HOLDINGS INC (XTNT) is 3 / 10.


What is the expected EPS growth for XTANT MEDICAL HOLDINGS INC (XTNT) stock?

The Earnings per Share (EPS) of XTANT MEDICAL HOLDINGS INC (XTNT) is expected to grow by 121.25% in the next year.